Health Care · In Vitro & In Vivo Diagnostic Substances

LNTH Lantheus Holdings, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1521036105 filings
Russell 2000

LNTH at a glance

Lantheus Holdings, Inc. (LNTH, SEC CIK 1521036) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Lantheus Holdings, Inc. (LNTH) reported revenue of $1.5 billion (up 0.5% from FY2024) and net income of $233.6 million. Diluted EPS was $3.41.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Lantheus Holdings, Inc. (LNTH) shares worth $2.6 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.5B
+0.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
34 funds
$2.6B · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Development, manufacturing, and commercialization of radiopharmaceutical and diagnostic imaging products
  • New launches: Acquisitions of Life Molecular (Neuraceq) and Evergreen, adding diagnostic imaging and CDMO services to portfolio in 2025
  • Strategic shifts: Discontinued AZEDRA in Q1 2024, sold TechneLite in 2026, focusing on higher-growth assets like Neuraceq and CDMO services
  • Notable metric: General & administrative expenses up $81.4M (42%) in 2025 due to acquisitions and litigation costs
  • Distinct fact: Paid $250M upfront for PNT2002 license but ceased development, deciding not to pursue NDA or further investment

Risk Factors

  • No specific or timely regulatory or legal risk detailed in the text
  • No concrete geopolitical or macroeconomic threat exposure disclosed
  • Operational risk from cybersecurity and data privacy requiring quarterly monitoring and oversight by Audit Committee
  • No named competitor or technology disrupting market environment mentioned
  • Key-person risk with CIO and CISO critical for risk management, each having ~30 years of industry experience

Management Discussion & Analysis

  • Operating cash flow $390.1M in 2025 vs $544.8M in 2024, decrease driven by acquisitions and working capital timing
  • Investing cash outflow $627.1M in 2025 vs $204.5M in 2024, 2025 includes $268.9M for Evergreen and $306.7M for Life Molecular acquisitions
  • Financing cash used $316.5M in 2025 vs $115.7M in 2024, due to $300M stock repurchase in 2025 vs $100M in 2024
  • Management highlights increased credit facility to $750M with extended maturity to 2029, expects cash plus credit availability to cover needs next 12+ months

AI summary of the LNTH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New merger risk: FTC Second Request on October 21, 2026 extended HSR review and could require divestitures or block closing
  • Regulatory risk: LNTH-2501 FDA Complete Response Letter cited unresolved third-party manufacturing conditions
  • Operational risk: PYLARIFY TruVu launch depends on PMF technology transfers, FDA approvals, and customer adoption beginning Q4 2026
  • Financial risk: merger termination fee of $228.0 million could reduce cash available for general corporate purposes
  • Asset risk: LNTH-2620 and LNTH-2515 impairment charges totaled $31.0 million after TAUKLARIFY approval changed development plans

Management Discussion & Analysis

  • Revenue $389.9M, up 1.5% YoY from $384.0M
  • Net income $22.4M, down 19.4% YoY from $27.8M
  • Best segment Neurology: Neuraceq revenue $45.6M, up 123.0% YoY
  • Operating margin 8.3% vs 11.4% YoY, calculated from reported operating income and revenue
  • Cash $683.6M; nine-month operating cash flow $319.3M vs $300.0M, no 2026 share repurchases
  • Near-term headwinds: PYLARIFY price decline, competition, LNTH-2501 CRL, Merger regulatory approvals pending

AI summary of the LNTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 8.01: Other Events

  • Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic
  • Sale remains subject to customary closing conditions and potential regulatory approvals
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Full operating results, financial figures, and management commentary in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $389.9M, up 1.5%, with Neuraceq up 123.0% and PYLARIFY down 0.7%
  • Adjusted EPS $1.68, up 32.3%, while GAAP EPS fell to $0.33 from $0.41
Filed Oct 22, 2026Full analysis →

Item 8.01: Other Events

  • FTC issued Second Requests on October 21, extending HSR review of Lantheus’s proposed merger with Curium
  • Waiting period extends 30 days after both parties substantially comply, unless terminated sooner by the FTC

AI summaries of LNTH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LNTH

Don't miss the next LNTH filing

  • Alerts as it files. A push when LNTH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LNTH, by share count.
  • Ask anything. An AI agent that reads every LNTH filing and answers with sources.

LNTH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Heino Mary AnneFNov 17, 2026$101.80
Marshall Robert J. Jr.FAug 31, 2026$100.96
Dinkelborg LudgerFAug 17, 2026$100.91
Brown KimberlyFAug 17, 2026$100.91
Baylor-Henry MinnieAMay 14, 2026-
Thrall James HAMay 14, 2026-
Pruden Gary JAMay 14, 2026-
LENO SAM RAMay 14, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$1.5B$1.5B
Gross Profit$709.5M$988.3M$942.0M
Operating Income-$457.0M$310.8M
Net Income$326.7M$312.4M$233.6M
Gross Margin-64.4%61.1%
Op. Margin-29.8%20.2%
Net Margin-20.4%15.2%
Balance Sheet
Total Assets$1.7B$2.0B$2.2B
Equity-$1.1B$1.1B
ROE-28.7%21.4%
Per Share
EPS$4.65$4.36$3.41
Cash Flow
Operating CF-$544.8M$390.1M

Source: XBRL data in Lantheus Holdings, Inc. (LNTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LNTH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LNTH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$2.65B
Q2 202634$3.66B
Q1 202633$2.31B
Q4 202531$2.11B
Q3 202534$1.81B
Q2 202532$2.76B
Q1 202533$2.16B
Q4 202428$1.77B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 259 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LNTH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 10, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 22, 2026Analysis-
8-KOct 14, 2026Analysis-
8-KOct 2, 2026Analysis-
8-KSep 21, 2026Analysis-
SC 13GSep 4, 2026-
SC 13DSep 4, 2026-
4Sep 2, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KAug 4, 2026Analysis-
8-KAug 3, 2026Analysis-
SC 13GJul 31, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-

Related Health Care companies

All Health Care →

LNTH SEC filings: frequently asked questions

Which institutions hold LNTH stock?

As of September 30, 2026, the largest Lantheus Holdings, Inc. (LNTH) holders among the 13F filers tracked by SignalX were BlackRock ($861.7 million), Vanguard Portfolio Management LLC ($311.5 million), Vanguard Capital Management LLC ($290.6 million), State Street Corp ($248.0 million), Millennium Management ($198.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LNTH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Lantheus Holdings, Inc. (LNTH) reported revenue of $1.5 billion (up 0.5% from FY2024) and net income of $233.6 million. Diluted EPS was $3.41. The figures come from the XBRL data in the 10-K.

What are the main risks in LNTH's latest 10-K?

In the 10-K filed February 26, 2026, Lantheus Holdings, Inc. (LNTH) flagged: No specific or timely regulatory or legal risk detailed in the text. No concrete geopolitical or macroeconomic threat exposure disclosed. (AI summary of the Risk Factors section.)

What did LNTH report in its latest 8-K?

Lantheus Holdings, Inc. (LNTH) filed an 8-K on November 10, 2026 reporting Item 8.01 (Other Events). Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic.

What are the latest LNTH SEC filings?

Lantheus Holdings, Inc. (LNTH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.

What is LNTH's SEC CIK number?

Lantheus Holdings, Inc. (LNTH)'s SEC Central Index Key (CIK) is 1521036. EDGAR lists every LNTH filing under that number.

Ask anything about LNTH

The research agent reads LNTH's filings, financials, insider trades and 13F holders, then answers with sources.